Scientific Program

VIRTUAL - ESO summer school - Caen, France 21-22-23 October 2021

Preliminary program

Prize of the best students’ presentation

Welcome 15’

New perspectives in endovascular treatment

Automated core-penumbra quantification in acute ischemic stroke : principles and different tools
Joseph Benzakoun (Paris) 20’
Controversy : Bridging therapy versus mechanical thrombectomy alone
Chair : Urs Fischer (Bern) & Yvo Roos (Rotterdam)
a. Presentation of the controversies by group 1 (students) 15’
b. Update on ongoing trials and unresolved issues and debate
Urs Fischer (Bern) & Yvo Roos (Rotterdam) 30’
Interventional vascular medicine with robotic assistance (Robocath)
Philippe Bencteux (Rouen) 15’

Future developments in IV thrombolytic agents

When tenectepalse should be preferred over alteplase ?
Jukka Putaala (Helsinki) 20’
Molecular imaging of clots to predict therapeutic response
Maxime Gauberti (Caen) 20’
How to improve the thrombolytic effect of alteplase and to reduce the risk of bleeding, alteplase mutants ?
Denis Vivien (Caen) 20’
New antithrombotic targets: antiGP6, antiGP1, von Willebrand
Sara Martinez de Lizarrondo (Caen) 20’

Discussion 20’

DAY 1 – Afternoon

Prehospital management of acute ischemic stroke

Mobile Stroke unit : Effects on process indicators, outcomes and cost utility
Heinrich Audebert (Berlin) 20’
Controversy : mother ship vs drip and ship
Chair : Emmanuel Touzé (Caen), Heinrich Audebert (Berlin)
a. Presentation of the controversies by group 2 (students) 15’
b. Utility of prehospital score to predict large artery disease
Guillaume Turc (Paris) 20’
c. Place of geographic modelling of best transport option for treatment of acute ischemic stroke
Ludwig Schlemm (London) 20’
d. Debate : Is there a need for randomized trials ?
Natalia Pérez de la Ossa (Barcelone), Richard Macrez (Caen) 30’

Virtual social event : to be determined

DAY 2 - Morning - Friday 22th October 2021

Genetics of stroke

How to interpret SNP, GWAS (with examples in stroke diseases)
Stéphanie Debette (Bordeaux) 30’
Key role of HTRA1 in cerebral SVD : showcasing the power of proteomics
Martin Dichgans (Munich) 30’
Clinical genetics of moyamoya angiopathy
Dominique Hervé (Paris) 30’

Small vessel diseases

Chair : David Werring (London)

Small vessel diseases: pathophysiology, classification, genetics
Eric Jouvent (Paris) 30’
Animal models of small vessel diseases
Anne Joutel (Paris) 30’
Cerebral vasculitis
Marcel Arnold (Bern) 30’
Imaging of sporadic haemorrhagic cerebral microangiopathies
Grégoire Boulouis (Paris) 30’

DAY 2 – Afternoon

Heart and stroke

Controversy : Whether to resume or not antithrombotic therapies after intracerebral haemorrhage
Chair : Karin Klijn (Nijmegen) & Marion Boulanger (Caen)
a. Presentation of the controversy by group 3 (students) 15’
b. Update on ongoing trials and unresolved issues and debate 30‘
Indications and complications of left appendage closure in stroke patients with atrial fibrillation
Valeria Caso (Perugia) 20’
Place of implantable cardiac monitors in cryptogenic stroke ?
Mira Katan (Zurich) 20’

Neurosurgery in stroke

Hemicraniectomy for ischaemic and haemorrhagic strok
Bart van der Worp (Utrecht) 20’
Local thrombolytic therapies in intraventricular haemorrhage: rationale, update of recent and future trials
Thomas Gaberel (Caen) 20’

Discussion 20’

Virtual social event: to be determined

DAY 3 - Morning - Saturday 23th October 2021

Virtual visit of the labs at Cyceron 30’

Diagnosis, risk factors and prognosis

BP target after stroke (ischemic vs. haemorrhagic, small vessel disease vs. others)
Chair : Alastair Webb (Oxford), Else Charlotte Sandset (Oslo)
a. Presentation of the controversies by group 4 (students) 15’
b. Update and recommendations
Diagnosis, significance, and management of blood pressure variability in cerebrovascular diseases
Alastair Webb (Oxford) 30’
Socioeconomic disparities and stroke
Marion Boulanger (Caen) 30’
Meditation in neurovascular and neurodegenerative disorders
Gael Chetelat (Caen) 30’